Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Conde, M. Isabel Prieto
  • Llop, Marta
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia

  • Pallarès, Victor|||0000-0002-9851-0345
  • Hoyos Colell, Montserrat|||0000-0002-1911-1734
  • Chillón, M. Carmen|||0000-0003-1624-6059
  • Barragán, Eva
  • Prieto Conde, M. Isabel
  • Llop, Marta
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Montesinos, Pau|||0000-0002-3275-5593
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Brunet, Salut|||0000-0003-0491-1672
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • González-Díaz, Marcos
  • Sierra, Jorge|||0000-0002-7966-0356
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
In recent years, several attempts have been made to identify novel prognostic markers in patients with intermediate-risk acute myeloid leukemia (IR-AML), to implement risk-adapted strategies. The non-receptor tyrosine kinases are proteins involved in regulation of cell growth, adhesion, migration and apoptosis. They associate with metastatic dissemination in solid tumors and poor prognosis. However, their role in haematological malignancies has been scarcely studied. We hypothesized that PTK2/FAK, PTK2B/PYK2, LYN or SRC could be new prognostic markers in IR-AML. We assessed PTK2, PTK2B, LYN and SRC gene expression in a cohort of 324 patients, adults up to the age of 70, classified in the IR-AML cytogenetic group. Univariate and multivariate analyses showed that PTK2B, LYN and PTK2 gene expression are independent prognostic factors in IR-AML patients. PTK2B and LYN identify a patient subgroup with good prognosis within the cohort with non-favorable FLT3/NPM1 combined mutations. In contrast, PTK2 identifies a patient subgroup with poor prognosis within the worst prognosis cohort who display non-favorable FLT3/NPM1 combined mutations and underexpression of PTK2B or LYN. The combined use of these markers can refine the highly heterogeneous intermediate-risk subgroup of AML patients, and allow the development of risk-adapted post-remission chemotherapy protocols to improve their response to treatment.